Investigating the discernible and distinct effects of platinum‑based chemotherapy regimens for metastatic triple‑negative breast cancer on time to progression
- Authors:
- Published online on: January 7, 2014 https://doi.org/10.3892/ol.2014.1782
- Pages: 866-870
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Platinum‑based chemotherapy regimens are frequently used in patients with triple‑negative breast cancer (TNBC). The aim of the current study was to assess whether or not platinum‑based chemotherapy is associated with an increased time to progression when compared with non‑platinum‑based regimens in TNBC and non‑TNBC. A retrospective analysis was conducted within a cohort of patients with metastatic breast cancer who received platinum‑based chemotherapy at a single institution. Data were collected for up to three lines of treatment for metastatic disease. Time to progression was determined for platinum‑based chemotherapy and non‑platinum‑based regimens for each line of treatment. Adjusted hazard ratios (HRs), together with 95% confidence intervals (CIs) were estimated comparing the time to progression associated with the use of platinum‑based chemotherapy versus non‑platinum‑based regimens. A total of 159 patients were included in the analysis, with 58 diagnosed with TNBC. Among the patients with TNBC, compared with non‑platinum‑based chemotherapy, no correlation was identified between platinum‑based chemotherapy and an improved time to progression [first line: HR, 0.97 (95% CI, 0.40‑2.35); second line: HR, 0.91 (95% CI, 0.42‑2.01); and third line: HR, 2.83 (95% CI, 0.73‑11.03)]. By contrast, patients with non‑TNBC appeared to improve with non‑platinum‑based chemotherapy [first line: HR, 2.57 (95% CI, 1.11‑5.99); second line: HR, 1.91 (95% CI, 1.00‑3.63); and third line: HR, 1.08 (95% CI, 0.53‑2.18)]. Although the present study was limited by the sample size and its observational nature, the results indicated that platinum‑based chemotherapy does not offer a discernible or distinct advantage compared with standard regimens in patients with TNBC, and is perhaps less efficacious in patients with non‑TNBC.
